Xintela AB Interim Report January – June 2023

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

Second quarter 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 18,401 (loss: 18,942).
Loss per share* was SEK 0.06 (loss: 0.21).

First half year 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 34,244 (loss: 35,326).
Loss per share* was SEK 0,11 (loss: 0,40)

Second quarter 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before and after tax totalled TSEK 11,151 (loss: 11,547).
Loss per share* was SEK 0.04 (loss: 0.13).

First half year 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before and after tax totalled TSEK 21,553 (loss: 22,589).
Loss per share* was SEK 0,07 (loss: 0,26).
At June 30, 2023, the equity/assets ratio** was 17 % (-99).

Significant events in the second quarter of 2023
» Xintela has started last dose level of XSTEM in knee osteoarthritis clinical study. (April 13, 2023)
» Xintela is carrying out a Rights issue of units of approximately SEK 123 million. (May 24, 2023)
» Xintela’s clinical study with XSTEM for knee osteoarthritis makes good progress. (June 1, 2023)
» Xintela publishes positive preclinical results from XSTEM treatment of ARDS. (June 9, 2023)
» Xintela completes XSTEM dosing at third and final dose level in knee osteoarthritis clinical study. (June 22, 2023)

Significant events after the end of the period
» Xintela publishes the outcome of the rights issue. (July 4, 2023)
» Xintela gets product patent in USA for chondrocyte-based products. (August 15, 2023)

The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela’s Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB.